GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (HKSE:02269) » Definitions » Cost of Goods Sold

WuXi Biologics (Cayman) (HKSE:02269) Cost of Goods Sold : HK$11,817 Mil (TTM As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Cost of Goods Sold?

WuXi Biologics (Cayman)'s cost of goods sold for the six months ended in Jun. 2024 was HK$5,624 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Jun. 2024 was HK$11,817 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. WuXi Biologics (Cayman)'s Gross Margin % for the six months ended in Jun. 2024 was 39.07%.

Cost of Goods Sold is also directly linked to Inventory Turnover. WuXi Biologics (Cayman)'s Inventory Turnover for the six months ended in Jun. 2024 was 2.78.


WuXi Biologics (Cayman) Cost of Goods Sold Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Cost of Goods Sold Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,650.44 6,687.00 9,541.93 11,163.49 11,770.61

WuXi Biologics (Cayman) Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,305.97 5,393.88 5,769.62 5,624.15 6,192.81

WuXi Biologics (Cayman) Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$11,817 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi Biologics (Cayman)  (HKSE:02269) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

WuXi Biologics (Cayman)'s Gross Margin % for the six months ended in Jun. 2024 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(9230.514 - 5624.146) / 9230.514
=39.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

WuXi Biologics (Cayman)'s Inventory Turnover for the six months ended in Jun. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


WuXi Biologics (Cayman) Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi Biologics (Cayman) Business Description

Traded in Other Exchanges
Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has a global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing.
Executives
Li Ge 2201 Interest of corporation controlled by you
Liu Xiaozhong 2401 A concert party to an agreement to buy shares
New Wuxi Life Science Holdings Limited 2201 Interest of corporation controlled by you
New Wuxi Life Science Limited 2201 Interest of corporation controlled by you
Wuxi Biologics Holdings Limited 2101 Beneficial owner
Wuxi Pharmatech (cayman) Inc. 2201 Interest of corporation controlled by you
Zhang Zhaohui 2401 A concert party to an agreement to buy shares
Blackrock, Inc. 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Citigroup Inc. 2502 Approved lending agent
Brown Brothers Harriman & Co. 2502 Approved lending agent
Zhao Ning 2202 Interest of your spouse
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you

WuXi Biologics (Cayman) Headlines

No Headlines